Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eN-Lac in children with perennial allergic rhinitis
NCT01116778Phase 3Completed
- Sponsor
- GenMont Biotech
- Start
- May 2010
- Primary completion
- Jan 2012
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in perennial allergic rhinitis (PAR) comparing eN-Lac® Capsules with Placebo Capsules (2 arms). Primary endpoint: Nasal Total Symptom Score at 8 weeks. Started May 2010; status: completed.
02
Drugs
eN-Lac
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01116778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116778.